Heparin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 38: | Line 38: | ||
<br> | <br> | ||
<br> | <br> | ||
[http://www.fda.gov/cder/drug/infopage/heparin/ FDA | [http://www.fda.gov/cder/drug/infopage/heparin/ FDA Label] | ||
<br> | <br> | ||
<br> | <br> | ||
Revision as of 20:53, 27 January 2014
Brand Names / Synonyms:
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Mechanism of action
Dosing and Administration
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA Label
FDA on Heparin
Publication Resources Return to top
Most Recent Articles on Heparin
Review Articles on Heparin
WikiDoc State of the Art Review
Articles on Heparin in N Eng J Med, Lancet, BMJ
Textbook Information on Heparin
Trial Resources Return to top
Ongoing Trials on Heparin at Clinical Trials.gov
Trial Results on Heparin
Guidelines & Evidence Based Medicine Resources Return to top
US National Guidelines Clearinghouse on Heparin
Cochrane Collaboration on Heparin
Cost effectiveness of Heparin
Media Resources Return to top
Powerpoint slides on Heparin
Images of Heparin
Podcasts & MP3s on Heparin
Videos on Heparin
Patient Resources Return to top
Patient Information from National Library of Medicine
Patient Resources on Heparin
Discussion Groups on Heparin
Patient Handouts on Heparin
Blogs on Heparin
Heparin in the News
Heparin in the Marketplace
International Resources Return to top
Heparin en Español
Adapted from the FDA Package Insert.